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Medication timeliness in emergency department in
pediatric sickle cell disease population presenting with
vaso-occlusive episode
Derrick L. Goubeaux, DO1; Kaitlyn Hoch, MBA 2; Gerald Woods, MD 1; Julie Routhieaux, RN PCNS 1; Maureen Guignon, RN BSN CPN3; Valerie McDougall Kestner, MD 3
1. Div ision of Hematology /Oncology /Bone Marrow Transplant, Children’s Mercy Kansas City ; 2. Quality Improv ement and Patient Saf ety , Children’s Mercy Kansas City ; 3. Div ision of Emergency and Urgent Care, Children’s Mercy Kansas City
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At Children’s Mercy Hospital (CMH), recommendation is initial intrav enous
(IV) dose of analgesia within 60 minutes of registration and subsequent
doses giv en ev ery 20 minutes as needed f or pain
If patient is determined to need admission f or f urther pain management,
goal at CMH is to initiate continuous inf usion (CI) of pain medication within
60 minutes of last bolus dose of pain

• At CMH, a delay in initiation of analgesia therapy upon arrival to ED as
w ell as delay in initiation of CI of pain medication has been observed
(Figure 1)
• Delays in medication administration lead to poor pain control

Aim Statements
By December 2018, reduce time to <60 minutes in patients w ith SCD
presenting to ED w ith VOE for:
1. Time interval betw een registration and 1st dose of pain medication in
80% of patients
2. Time interval betw een 1st and 3rd dose of pain medication in 80% of
patients
3. Time interval betw een initiation of continuous infusion of pain
medication and 3rd dose of pain medication in 60% patients
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Baseline data w as obtained by retrospective chart review over a
three month period, represented on Figures 2, 3, and 4
•
•
•

Figure 1: Process map outlining current recommended timing (in green) along with current CMH timing (in red) f rom registration to 1 st dose
of pain medication, 1st dose to 3rd dose of IV pain medication, and 3rd dose to initiation of CI of pain medication.
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For the initial dosing, all 3 months were abov e baseline with one month
reaching target at 80%
For time between f irst and third dose of pain medication, 2 of 3 months
were abov e baseline
For time between third dose and initiation of CI, all 3 months were
abov e baseline

Initial qualitative response from ED staff and nursing has been
positive regarding initial countermeasures and care of the patients

Conclusions and Future Direction
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Figure 2: Outlines data on time f rom registration to 1 st dose of
pain medication and percentage of patients meeting aim of <60
minutes f rom registration to 1st dose
Figure 3: Outlines data on time f rom to 1st dose to 3rd dose of
pain medication and percentage of patients meeting aim of <60
minutes f rom 1st dose to 3rd dose of pain medication

Figure 4: Outlines data on time f rom 3rd dose to initiation of CI of
pain medication and percentage of patients meeting aim of <60
minutes f rom 3rd dose to initiation of CI of pain medication
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Figure 4
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Figure 3

3rd dose to continuous infusion
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A median of 58.8% of patients were receiv ing an initial dose of
analgesic therapy within 60 minutes of registration
Sixty minutes between f irst and third dose occurred in 53.8% of patients
Initiation of CI was occurring in 8.3% of patients within 60 minutes of the
third dose of opioids

Over the first three PDSA cycles (June 2018 – August 2018)
improvement has been noted across all 3 aims.
•

Registration to 1st dose

Methods
Scope:
Pediatric patients w ith SCD presenting to the ED w ith VOE
Process Measure:
Utilization of intranasal fentanyl for initial pain medication option; adjust
reassessment prompt follow ing bolus dose to every 20 minutes;
consolidate initial ED pow er plan (PP) and separate CI PP into single PP
Outcome Measure:
Percentage of patients meeting <60 minute time parameter for 1st dose of
pain medication, 1st to 3rd dose of pain medication, and 3rd dose of pain
medication to initiation of CI of pain medication
Balancing Measures:
Staff dissatisfaction with more rapid delivery of pain medications and
initiation of CI in ED; patient/parent concern w ith effectiveness/comfort of
intranasal pain medications

Results

Percent of patients meeting target

Vaso-occlusive episode (VOE) is the most common acute complication
for individuals w ith sickle cell disease (SCD) and the most common
reason to seek medical care
• Recommendations are rapid initiation of analgesia therapy upon arrival
to emergency department (ED) w ith timely subsequent doses given as
needed for pain
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Background

• Improved efficiency in time to initiation of analgesic support has
been show n to lead to improved pain management in patients w ith
SCD presenting to the ED for VOE
•
•

It is anticipated that with the ev entual achiev ement of the aims, a
decreased admission rate will be noted
For those indiv iduals still requiring f urther analgesic support, it is f elt
f aster initiation of CI will lead to quicker control of VOE and,
subsequently , shorter hospitalizations

• Integration of process measures into PP w ill allow for sustainable
improvement/development of new standard
•

Monitoring quantitativ e results will allow f or identif ication of when PP not
working/has f ailed

• Additional countermeasures are currently being vetted in
anticipation to adding to the current interventions to further improve
the project’s efforts and maintain the long-term success of this
project over time
•

Plan will be to continue to run monthly PDSA cy cles f or a total of 6
months to ev aluate response of timing to initial adjustments bef ore
integrating f urther interv entions

• At completion of a 12 month period of monthly data collection, data
collection and review will then be done quarterly
•
•

Presented at quarterly Hematology /Oncology /ED meeting
Qualitativ e data will also be discussed to ensure continued improv ement
established by current project

